Overall Abstract The National Resource for Translational and Developmental Proteomics, or NRTDP, proposes a constellation of activities in its second phase of operation. After launching in 2015 and establishing functional programs in each mission of a P41 BTRR, we now turn toward the proposed granting period from 2020 ? 2025 to develop new technologies and translate them by enabling both practitioners to analyze proteoforms and many collaborators to understand their biology more deeply. Consistent with changes in the P41 program, we place major emphasis on enabling basic and clinical research in proteomics, reduction to practice to extend innovations to early adopters of new implementations of top-down proteomics, which is itself a new concept to many we encounter. We also embrace mechanisms including corporate partnerships, community engagement, training and dissemination to ensure a sustainable impact even after the sunset of this P41 National Resource. After booting up our operation, we now posit three new Technology Research and Development Projects, six new Driving Biomedical Projects, a highly dynamic set of collaborative projects and an array of Community Engagement activities to continue serving our unique role within the set of P41 Resources currently supported by NIGMS. The technology and support emanating from our resource will continue to provide collaborators with orthogonal data streams and further demonstrate the value of measuring proteins more precisely than is possible with current-generation technology of ?bottom-up? proteomics. From heart disease to cancer research, neurology and age-related disorders to immunology, the analysis of proteins and proteoforms and their post- translational modifications will continue to unveil underlying molecular mechanisms through new and cell-specific technologies for precision proteomics. This will enable clinicians and cell biologists across four major disease areas, and significantly bolster American interests with an internationally-recognized excellence in a new style of mass spectrometry-based proteomics that complements existing areas of investment across the nation. The geographical distribution of collaborators and training activities are consistent with a mature resource that reaches the level of operation envisaged in the original grant proposal in 2015. The institutional support is very strong from an environment of Northwestern University on both its basic science and medical research campuses in the greater Chicago area. Leveraging a team of professional proteomicists with diverse backgrounds and experiences, the NRTDP has proven to be a highly capable enterprise that returns strongly on programmatic support received by NIGMS. As a unit, we place high value on attentiveness to the spirit and the letter of the P41 program, and also seek to synergize with other P41s within the current portfolio supported by the NIGMS and NIH.

Public Health Relevance

The activities of this grant represent a major upgrade in the technology to precisely analyze protein molecules from cells and the human body. From model systems and humans, proteins are measured from cell culture, cells, fluids, and solid tissue to better understand and detect mechanisms and markers of human disease. Technological improvements assist the collaborating clinical and research labs directly, but also the field of protein measurement science in general through robust programs for training, dissemination and community engagement.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Biotechnology Resource Grants (P41)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Krepkiy, Dmitriy
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Northwestern University at Chicago
Organized Research Units
United States
Zip Code
Kenney, Grace E; Dassama, Laura M K; Pandelia, Maria-Eirini et al. (2018) The biosynthesis of methanobactin. Science 359:1411-1416
Swaroop, Alok; Oyer, Jon A; Will, Christine M et al. (2018) An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia. Oncogene :
Davis, Roderick G; Park, Hae-Min; Kim, Kyunggon et al. (2018) Top-Down Proteomics Enables Comparative Analysis of Brain Proteoforms Between Mouse Strains. Anal Chem 90:3802-3810
LeDuc, Richard D; Schwämmle, Veit; Shortreed, Michael R et al. (2018) ProForma: A Standard Proteoform Notation. J Proteome Res 17:1321-1325
Aebersold, Ruedi; Agar, Jeffrey N; Amster, I Jonathan et al. (2018) How many human proteoforms are there? Nat Chem Biol 14:206-214
Turcan, Sevin; Makarov, Vladimir; Taranda, Julian et al. (2018) Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence. Nat Genet 50:62-72
Lyon, Yana A; Riggs, Dylan; Fornelli, Luca et al. (2018) The Ups and Downs of Repeated Cleavage and Internal Fragment Production in Top-Down Proteomics. J Am Soc Mass Spectrom 29:150-157
Fornelli, Luca; Toby, Timothy K; Schachner, Luis F et al. (2018) Top-down proteomics: Where we are, where we are going? J Proteomics 175:3-4
Fisher, Oriana S; Kenney, Grace E; Ross, Matthew O et al. (2018) Characterization of a long overlooked copper protein from methane- and ammonia-oxidizing bacteria. Nat Commun 9:4276
Gruppuso, Philip A; Boylan, Joan M; Zabala, Valerie et al. (2018) Stability of histone post-translational modifications in samples derived from liver tissue and primary hepatic cells. PLoS One 13:e0203351

Showing the most recent 10 out of 53 publications